Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions
Authors:
- 1 May 1998
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 43 (5) , 561-575
Abstract
Orally administered levodopa remains the most effective symptomatic treatment for Parkinson's disease (PD). The introduction of levodopa therapy is often delayed, however, because of the fear that it might be toxic for the remaining dopaminergic neurons and, thus, accelerate the deterioration of patients. However, in vivo evidence of levodopa toxicity is scarce. We have evaluated the effects of a 6‐month oral levodoapa treatment on several dopaminergic markers, in rats with moderate or severe 6‐hydroxydopamine‐induced lesions of mesencephalic dopamine neurons and sham‐lesioned animals. Counts of tyrosine hydroxylase (TH)‐immunoreactive neurons in the substantia nigra and ventral tegmental area showed no significant difference between levodopa‐treated and vehicle‐treated rats. In addition, for rats of the sham‐lesioned and severely lesioned groups, immunoradiolabeling for TH, the dopamine transporter (DAT), and the vesicular monoamine transporter (VMAT2) at the striatal level was not significantly defferent between rats treated with levodopa or vehicle. It was unexpected that quantification of immunoautoradiograms showed a partial recovery of all three dopaminergic markers (TH, DAT, and VMAT2) in the denervated territories of the striatum of moderately lesioned rats receiving levodopa. Furthermore, the density of TH‐positive fibers observed in moderately lesioned rats was higher in those treated chronically with levodopa than in those receiving vehicle. Last, that chronic levodopa administration reversed the up‐regulation of D2 dopamine receptors seen in severely lesioned rats provided evidence that levodopa reached a biologically active concentration at the basal ganglia. Our results demonstrate that a pharmacologically effective 6‐month oral levodopa treatment is not toxic for remaining dopamine neurons in a rat model of PD but instead promotes the recovery of striatal innervation in rats with partial lesions.Keywords
This publication has 86 references indexed in Scilit:
- Protective effect of carbidopa on hydroxyl radical generation in the rat striatum by dopamineNeuroscience Letters, 1996
- Does levodopa therapy delay death in Parkinson's disease? A review of the evidenceMovement Disorders, 1995
- Long‐Term Induction of Tyrosine Hydroxylase Expression: Compensatory Response to Partial Degeneration of the Dopaminergic Nigrostriatal System in the Rat BrainJournal of Neurochemistry, 1995
- Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigraBrain Research, 1994
- Quantitative Autoradiography of Tyrosine Hydroxylase Immunoreactivity in the Rat BrainJournal of Neurochemistry, 1991
- Dopamine increases the expression of tyrosine hydroxylase and aromatic amino acid decarboxylase in primary cultures of fetal neuronsDevelopmental Brain Research, 1991
- Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in cultureJournal of Neuroscience Research, 1990
- Effects ofl-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated ratsBrain Research, 1990
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989
- Levodopa in Parkinson disease: A long‐term appraisal of mortalityAnnals of Neurology, 1978